ATAI Life Sciences (ATAI) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ATAI ATAI Life Sciences

Watchlist

1.610
+0.240+17.52%

Close Nov 15 16:00 ET

1.670
+0.060+3.73%

Pre 07:05 ET

270.16MMarket Cap-2012P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Maxim Group Maintains ATAI Life Sciences(ATAI.US) With Buy Rating, Maintains Target Price $6
Moomoo NewsNov 16 13:31 ET · Ratings
ATAI Life Sciences: Strategic Advancements and Strong Financials Underpin Buy Rating
TipRanksNov 16 13:15 ET
Express News | U.S.-Listed Shares of ATAI Life Sciences up 9.1%
ReutersNov 15 09:34 ET
RFK and the 'MAHA Trade': Vaccine Makers Down, Psychedelic Shares up
Seeking AlphaNov 15 06:02 ET
ATAI Life Sciences | 10-Q/A: Quarterly report (Amendment)
SECNov 14 16:43 ET · Announcements
Atai Life Sciences Advances Psychedelic Treatments in Q3 2024
TipRanksNov 13 23:34 ET

Comments

Simon 5183

Sep 19 00:28

$ATAI Life Sciences (ATAI.US)$Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
迷幻药品市场预计到2028年将增长137亿美元，受精神健康障碍和人工智能整合驱动

Jaguar8

Aug 13 08:23

NEWS

$ATAI Life Sciences (ATAI.US)$
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
atai Life Sciences (NASDAQ: ATAI)announced positive preliminary results from its Phase 1b trial of VLS-01, a proprietary oral transmucosal film formulation of N,N-dimethyltryptamine (DMT). The trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of VLS-01 compared to intravenous DMT in healthy participants.
Key findings include:
D...